NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCR NovoCure

Pre-Mkt 12-09 07:19:40 EST

12.06

-0.05

-0.41%

盘前12.15

+0.09+0.75%

05:22 EST

High12.33	Low11.82	Vol1.40M
Open12.24	D1 Closing12.11	Amplitude4.17%
Mkt Cap1.35B	Tradable Cap1.14B	Total Shares111.98M
T/O16.89M	T/O Rate1.49%	Tradable Shares94.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCR","market":"US","secType":"STK","nameCN":"NovoCure","latestPrice":12.06,"timestamp":1765227600000,"preClose":12.11,"halted":0,"volume":1403958,"hourTrading":{"tag":"盘前","latestPrice":12.15,"preClose":12.06,"latestTime":"05:22 EST","volume":25,"amount":303.75,"timestamp":1765275741649},"delay":0,"floatShares":94147892,"shares":111981981,"eps":-1.60741,"marketStatus":"Pre-Mkt","change":-0.05,"latestTime":"12-09 07:19:40 EST","open":12.24,"high":12.325,"low":11.82,"amount":16889916.59097,"amplitude":0.041701,"askPrice":13,"askSize":10,"bidPrice":11.5,"bidSize":130,"shortable":3,"etf":0,"ttmEps":-1.60741,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765290600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1443758400000,"exchange":"NASDAQ","adjPreClose":12.06,"preHourTrading":{"tag":"盘前","latestPrice":12.15,"preClose":12.06,"latestTime":"05:22 EST","volume":25,"amount":303.75,"timestamp":1765275741649},"postHourTrading":{"tag":"盘后","latestPrice":12.06,"preClose":12.06,"latestTime":"17:28 EST","volume":23349,"amount":281591.7875,"timestamp":1765232919096},"volumeRatio":0.5670195566926745,"impliedVol":0.6063,"impliedVolPercentile":0.4779},"requestUrl":"/m/hq/s/NVCR/tweets","defaultTab":"tweets","newsList":[{"id":"2588722709","title":"How Investors Are Reacting To NovoCure (NVCR) CEO Transition as Frank Leonard Takes the Helm","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722709","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722709?lang=en_us&edition=fundamental","pubTime":"2025-12-02 03:24","pubTimestamp":1764617094,"startTime":"0","endTime":"0","summary":"On December 1, 2025, NovoCure announced that Ashley Cordova resigned from her role as Chief Executive Officer and Board Director, effective at the end of November, with Frank Leonard, formerly President and an established leader within the company, appointed as the new CEO.\nFrank Leonard’s long-standing experience in global operations, product development, and business growth at NovoCure may provide important continuity and insight as the company enters its next phase.\nWe’ll explore how...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/how-investors-are-reacting-to-novocure-nvcr-ceo-transition-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/how-investors-are-reacting-to-novocure-nvcr-ceo-transition-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NVCR","BK4211","BK4548","BK4588","BK4082","BK4585","ISBC","BK4534"],"gpt_icon":0},{"id":"2588727791","title":"BRIEF-Novocure Appoints Company President Frank Leonard As Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727791","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727791?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:58","pubTimestamp":1764593921,"startTime":"0","endTime":"0","summary":"BRIEF-Novocure Appoints Company President Frank Leonard As Chief Executive OfficerDec 1 (Reuters) - Novocure Ltd NVCR.O:NOVOCURE APPOINTS COMPANY PRESIDENT FRANK LEONARD AS CHIEF EXECUTIVE OFFICERNOVO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA68GCYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4082","BK4534","NVCR","BK4548"],"gpt_icon":0},{"id":"2588727626","title":"NovoCure Names Frank Leonard as Chief Executive","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727626","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727626?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:40","pubTimestamp":1764592803,"startTime":"0","endTime":"0","summary":"NovoCure (NVCR) said Monday it has appointed Frank Leonard as chief executive, effective immediately, replacing Ashley Cordova, who has resigned.Leonard previously served as the company's president.NovoCure shares were down 1.6% in recent premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","BK4585","BK4082","NVCR","BK4588","BK4534"],"gpt_icon":0},{"id":"2588774724","title":"Novocure Names Frank Leonard as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588774724","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588774724?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:01","pubTimestamp":1764590485,"startTime":"0","endTime":"0","summary":"Novocure Ltd. has appointed Frank Leonard as Chief Executive Officer, effective immediately. Leonard, who previously served as the company's President, succeeds Ashley Cordova following her resignation. Leonard has been with Novocure since 2010 and has held various leadership roles within the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL3wMfwz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4082","BK4534","NVCR","BK4548"],"gpt_icon":0},{"id":"2588724278","title":"Novocure Ltd - Frank Leonard Succeeds Ashley Cordova as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724278","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724278?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA68GCYX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4534","BK4585","NVCR","BK4548","BK4082"],"gpt_icon":0},{"id":"2586251578","title":"Novocure to Present at Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2586251578","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586251578?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:00","pubTimestamp":1764158426,"startTime":"0","endTime":"0","summary":"Novocure Ltd. will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. Executive Chairman William Doyle is scheduled to take part in a fireside chat at 11:30 a.m. ET and will also conduct one-on-one meetings with investors during the event. A live audio webcast of the presentation will be available on the Investor Relations page of Novocure's website and can be replayed for at least 14 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL5tDjgj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4548","BK4588","BK4082","BK4585","BK4534"],"gpt_icon":0},{"id":"2583307769","title":"Should Rising Losses Despite Higher Sales Require Action From NovoCure (NVCR) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583307769","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583307769?lang=en_us&edition=fundamental","pubTime":"2025-11-13 02:39","pubTimestamp":1762972758,"startTime":"0","endTime":"0","summary":"NovoCure reported its third quarter 2025 results, showing sales of US$167.2 million and a net loss of US$37.27 million, alongside a nine-month net loss of US$111.73 million on sales of US$481 million.\nWhile revenue increased year-over-year, the company's rising net losses may fuel ongoing debates about the pace toward profitability and margin improvement.\nWe'll take a closer look at how rising net losses alongside higher sales may shape the outlook for NovoCure’s investment narrative.\nThese...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/should-rising-losses-despite-higher-sales-require-action-fro","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/should-rising-losses-despite-higher-sales-require-action-fro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","NVCR"],"gpt_icon":0},{"id":"2582537323","title":"Novocure to Present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2582537323","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582537323?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:01","pubTimestamp":1762948894,"startTime":"0","endTime":"0","summary":"Novocure Ltd. will participate in the Jefferies Global Healthcare Conference in London on November 19, 2025. Chief Executive Officer Ashley Cordova will present on behalf of the company at 2:00 p.m. GMT, joined by Chief Financial Officer Christoph Brackmann for one-on-one investor meetings. A live audio webcast of the presentation will be available on Novocure's Investor Relations website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL1hPqhv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4585","BK4588","BK4082","NVCR","BK4534"],"gpt_icon":0},{"id":"2582733327","title":"NovoCure (NVCR): Assessing Valuation Following Q3 Sales Growth and Rising Net Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2582733327","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582733327?lang=en_us&edition=fundamental","pubTime":"2025-11-11 10:23","pubTimestamp":1762827820,"startTime":"0","endTime":"0","summary":"NovoCure (NVCR) has announced its third-quarter results, with sales climbing to $167 million compared to last year. Net losses also widened both for the quarter and the nine-month period.\nSee our latest analysis for NovoCure.\nNovoCure’s latest earnings come after a challenging stretch for shareholders, with a 1-year total shareholder return of -36.8% and the share price now at $11.27, down more than 62% year-to-date. Despite recent momentum shifts and a few short-term price bumps, the stock’s...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-assessing-valuation-following-q3-sales-growth","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-assessing-valuation-following-q3-sales-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NVCR"],"gpt_icon":0},{"id":"2580443298","title":"NovoCure’s Mixed Q3: Growth Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2580443298","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580443298?lang=en_us&edition=fundamental","pubTime":"2025-11-01 08:53","pubTimestamp":1761958383,"startTime":"0","endTime":"0","summary":"NovoCure Ltd. (($NVCR)) has held its Q3 earnings call. Read on for the main highlights of the call. NovoCure Ltd. recently held its third-quarter e...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novocures-mixed-q3-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novocures-mixed-q3-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","NVCR","BK4585","BK4588","BK4082","BK4534"],"gpt_icon":0},{"id":"2579743389","title":"Novocure Ltd. Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579743389","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579743389?lang=en_us&edition=fundamental","pubTime":"2025-10-31 12:57","pubTimestamp":1761886661,"startTime":"0","endTime":"0","summary":"NovoCure Ltd. ( ($NVCR) ) has released its Q3 earnings. Here is a breakdown of the information NovoCure Ltd. presented to its investors. Novocure L...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novocure-ltd-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novocure-ltd-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4588","BK4082","NVCR","BK4534","BK4585"],"gpt_icon":0},{"id":"2579512730","title":"Novocure Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2579512730","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579512730?lang=en_us&edition=fundamental","pubTime":"2025-10-31 00:46","pubTimestamp":1761842760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2025 12:46 ET (16:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"gpt_icon":0},{"id":"2579122845","title":"Novocure price target raised to $42 from $38 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2579122845","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579122845?lang=en_us&edition=fundamental","pubTime":"2025-10-31 00:15","pubTimestamp":1761840918,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Novocure (NVCR) to $42 from $38 and keeps a Buy rating on the shares following the Q3 report. The...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novocure-price-target-raised-to-42-from-38-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novocure-price-target-raised-to-42-from-38-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCR"],"gpt_icon":0},{"id":"1187069858","title":"Stock Track | NovoCure Plunges 5.56% Despite Better-Than-Expected Q3 Revenue as Losses Widen","url":"https://stock-news.laohu8.com/highlight/detail?id=1187069858","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187069858?lang=en_us&edition=fundamental","pubTime":"2025-10-30 22:35","pubTimestamp":1761834940,"startTime":"0","endTime":"0","summary":"NovoCure (NVCR) shares plummeted 5.56% in intraday trading on Thursday, despite the company reporting better-than-expected third-quarter revenue. The sharp decline comes as investors appear to focus...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NVCR"],"gpt_icon":0},{"id":"2579561149","title":"Novocure reports Q3 EPS (33c), consensus (42c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2579561149","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579561149?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:10","pubTimestamp":1761826251,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $167.2M, consensus $158.94M. “Q3 was a solid quarter with steady commercial execution in glioblastoma, geographic expansion, and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novocure-reports-q3-eps-33c-consensus-42c-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novocure-reports-q3-eps-33c-consensus-42c-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCR"],"gpt_icon":0},{"id":"1158150329","title":"Stock Track | NovoCure Surges 6.16% Pre-Market on Strong Q3 Results and Regulatory Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=1158150329","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158150329?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:58","pubTimestamp":1761825505,"startTime":"0","endTime":"0","summary":"NovoCure (NASDAQ: NVCR) shares soared 6.16% in pre-market trading on Thursday following the release of its third-quarter 2025 financial results, which surpassed analyst expectations. The oncology...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NVCR"],"gpt_icon":0},{"id":"2579655117","title":"Novocure Reports Q3 Revenue Up 8% to $167 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2579655117","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579655117?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:02","pubTimestamp":1761822175,"startTime":"0","endTime":"0","summary":"Novocure Ltd. reported its third quarter 2025 financial results, posting net revenues of $167.2 million, an 8% increase compared to the same period in 2024. The revenue boost was primarily attributed to active patient growth and $3.3 million in exchange rate benefits. As of September 30, 2025, there were 4,416 active patients on therapy. Regional revenue contributions included $96.6 million from the U.S., $20.3 million from Germany, $19.6 million from France, and $9.4 million from Japan, with other active markets contributing $15.7 million. The company also announced that its premarket approval application for Tumor Treating Fields therapy use in pancreatic cancer is under substantive review by the U.S. Food and Drug Administration. A topline data readout from the Phase 3 TRIDENT clinical trial in newly diagnosed glioblastoma is expected in the second quarter of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL8HrMCG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4534","BK4082","BK4588","NVCR","BK4585"],"gpt_icon":0},{"id":"2579117660","title":"Novocure Receives Japanese Approval for Optune Lua in Advanced NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2579117660","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579117660?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:01","pubTimestamp":1761822104,"startTime":"0","endTime":"0","summary":"Novocure Ltd. recently announced several significant regulatory milestones for its Tumor Treating Fields  therapies. In August 2025, Optune Gio received coverage from the Spanish National Health System for adult patients with newly diagnosed glioblastoma. Additionally, in September 2025, the Japanese Ministry of Health, Labour and Welfare approved Optune Lua for use in combination with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer  who have progressed following platinum-based chemotherapy. Novocure also noted that its premarket approval application for TTFields therapy in pancreatic cancer is under substantive review by the U.S. Food and Drug Administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL2WxtR9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4588","BK4082","BK4534","BK4585","BK4548"],"gpt_icon":0},{"id":"2579178761","title":"NovoCure Q3 EPS $(0.33) Beats $(0.42) Estimate, Sales $167.204M Beat $159.189M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2579178761","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579178761?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:01","pubTimestamp":1761822065,"startTime":"0","endTime":"0","summary":"NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.42) by 21.62 percent. This is a 17.86 percent decrease over losses of $(0.28) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/10/48522415/novocure-q3-eps-0-33-beats-0-42-estimate-sales-167-204m-beat-159-189m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"gpt_icon":0},{"id":"2579120911","title":"BRIEF-Novocure Q3 Revenue USD 167.204 Million Vs. IBES Estimate USD 158.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2579120911","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579120911?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:00","pubTimestamp":1761822047,"startTime":"0","endTime":"0","summary":"BRIEF-Novocure Q3 Revenue USD 167.204 Million Vs. IBES Estimate USD 158.6 Million\n\n\nOct 30 (Reuters) - Novocure Q3 net income USD -37.27 million.\n\nQ3 operating income USD -36.021 million\nQ3 gross profit USD 122.475 million\nQ3 pretax profit USD -30.022 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nPLX77C576:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4082","BK4548","BK4534","BK4585","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novocure.com","stockEarnings":[{"period":"1week","weight":0.0325},{"period":"1month","weight":0.1044},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.3053},{"period":"1year","weight":-0.5687},{"period":"ytd","weight":-0.5953}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0189},{"period":"3month","weight":0.0512},{"period":"6month","weight":0.1368},{"period":"1year","weight":0.1247},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":-0.024854},{"month":2,"riseRate":0.4,"avgChangeRate":-0.01214},{"month":3,"riseRate":0.5,"avgChangeRate":-0.017692},{"month":4,"riseRate":0.5,"avgChangeRate":0.079553},{"month":5,"riseRate":0.8,"avgChangeRate":0.134604},{"month":6,"riseRate":0.4,"avgChangeRate":-0.026837},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004605},{"month":8,"riseRate":0.6,"avgChangeRate":0.019977},{"month":9,"riseRate":0.4,"avgChangeRate":-0.021376},{"month":10,"riseRate":0.2,"avgChangeRate":-0.091688},{"month":11,"riseRate":0.636364,"avgChangeRate":0.077306},{"month":12,"riseRate":0.454545,"avgChangeRate":0.059004}],"exchange":"NASDAQ","name":"NovoCure","nameEN":"NovoCure"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NovoCure,NVCR,NovoCure股票,NovoCure股票老虎,NovoCure股票老虎国际,NovoCure行情,NovoCure股票行情,NovoCure股价,NovoCure股市,NovoCure股票价格,NovoCure股票交易,NovoCure股票购买,NovoCure股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction